These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 28881501

  • 1. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
    Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, Mehra N, van Erp NP.
    Br J Clin Pharmacol; 2018 Jan; 84(1):122-129. PubMed ID: 28881501
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors.
    Zhong YY, Anton A, Xie O, Tan N, O'Haire S, Maleki S, Inderjeeth AJ, Parente P, Spain L, Gibbs P, Tran B.
    JCO Oncol Pract; 2024 Sep; 20(9):1231-1242. PubMed ID: 38805663
    [Abstract] [Full Text] [Related]

  • 4. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
    Conde-Estévez D, Henríquez I, Muñoz-Rodríguez J, Rodriguez-Vida A.
    Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):601-613. PubMed ID: 36111393
    [Abstract] [Full Text] [Related]

  • 5. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
    Efstathiou E, Titus M, Wen S, Troncoso P, Hoang A, Corn P, Prokhorova I, Araujo J, Dmuchowski C, Melhem-Bertrandt A, Patil S, Logothetis CJ.
    Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.
    Slovin S, Clark W, Carles J, Krivoshik A, Park JW, Wang F, George D.
    JAMA Oncol; 2018 May 01; 4(5):702-706. PubMed ID: 29222530
    [Abstract] [Full Text] [Related]

  • 8. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital.
    Ramasubbu SK, Mahato SK, Agnihotri A, Pasricha RK, Nath UK, Das B.
    Cancer Treat Res Commun; 2021 May 01; 26():100277. PubMed ID: 33348276
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study.
    Kim SH, Suh Y, Ah YM, Jun K, Lee JY.
    Support Care Cancer; 2020 Aug 01; 28(8):3617-3626. PubMed ID: 31802250
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
    Siemens DR, Klotz L, Heidenreich A, Chowdhury S, Villers A, Baron B, van Os S, Hasabou N, Wang F, Lin P, Shore ND.
    J Urol; 2018 Jan 01; 199(1):147-154. PubMed ID: 28827103
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
    Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C.
    Ann Pharmacother; 2013 Mar 01; 47(3):324-32. PubMed ID: 23482734
    [Abstract] [Full Text] [Related]

  • 18. Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting.
    Jung SI, Kim MS, Jeong CW, Kwak C, Hong SK, Kang SH, Joung JY, Lee SH, Yun SJ, Kim TH, Park SW, Jeon SS, Kang M, Lee JY, Chung BH, Hong JH, Ahn H, Kim CS, Kwon DD.
    Investig Clin Urol; 2020 Jan 01; 61(1):19-27. PubMed ID: 31942459
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
    Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung D, Parli T, Krivoshik A, Beer TM.
    Eur Urol Oncol; 2019 Nov 01; 2(6):677-684. PubMed ID: 31274110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.